2006
Effects of a novel tylophorine analog on collagen‐induced arthritis through inhibition of the innate immune response
You X, Pan M, Gao W, Shiah H, Tao J, Zhang D, Koumpouras F, Wang S, Zhao H, Madri JA, Baker D, Cheng Y, Yin Z. Effects of a novel tylophorine analog on collagen‐induced arthritis through inhibition of the innate immune response. Arthritis & Rheumatism 2006, 54: 877-886. PMID: 16508970, DOI: 10.1002/art.21640.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisBone marrow-derived dendritic cellsMarrow-derived dendritic cellsInnate immune responseDendritic cellsProinflammatory cytokinesTylophorine analogsImmune responseOnset of CIAProgression of CIACytometric bead array analysisTumor necrosis factor alphaB cell antibody responseDevelopment of arthritisNecrosis factor alphaT cell proliferationBead array analysisNovel therapeutic agentsEnzyme-linked immunosorbent assayInflammatory arthritisJoint inflammationInflammatory cytokinesAntibody responseClinical severityPathologic changes
1995
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
Wang Y, Rollins S, Madri J, Matis L. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 1995, 92: 8955-8959. PMID: 7568051, PMCID: PMC41086, DOI: 10.1073/pnas.92.19.8955.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisRheumatoid arthritisComplement activationAnti-C5 mAbInflammatory joint diseaseOnset of arthritisMonoclonal antibody therapyTerminal complement activationAttractive therapeutic targetJoint inflammationAntibody therapySystemic administrationJoint diseaseNumerous disease statesImmunized animalsArthritisAnimal modelsTherapeutic targetPotent mediatorTerminal complement componentsActivated componentsComplement cascadeComplement componentsComplement systemMonoclonal antibodies